Targeted delivery of molecules modulating the toxic impact of TDP-43 alterations, such as the ones presented in the first paragraph on chromatin modifiers, could represent a path for new therapies and could, notably, benefit from novel pharmacological approaches derived from research against cancer [204]. The gene discussed is TARDBP; the disease is cancer.